



# Heme–thiolate sulfenylation of human cytochrome P450 4A11 functions as a redox switch for catalytic inhibition

Received for publication, April 20, 2017, and in revised form, May 16, 2017. Published, Papers in Press, May 22, 2017, DOI 10.1074/jbc.M117.792200

Matthew E. Albertolle<sup>†1</sup>, Donghak Kim<sup>‡5</sup>, Leslie D. Nagy<sup>‡</sup>, Chul-Ho Yun<sup>¶</sup>, Ambra Pozzi<sup>||\*\*2</sup>, Üzen Savas<sup>‡‡</sup>, Eric F. Johnson<sup>‡‡</sup>, and F. Peter Guengerich<sup>‡3</sup>


From the <sup>†</sup>Department of Biochemistry, Vanderbilt University School of Medicine, Nashville, Tennessee 37232-0146, the <sup>‡</sup>Department of Biological Sciences, Konkuk University, Seoul 05025, Korea, the <sup>¶</sup>School of Biological Sciences and Technology, Chonnam National University, Gwangju 61186, Korea, the <sup>||</sup>Department of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee 37232-6602, the <sup>\*\*</sup>Veterans Affairs Medical Center, Nashville, Tennessee 37232, and the <sup>‡‡</sup>Department of Molecular Medicine, The Scripps Research Institute, La Jolla, California 92037

Edited by Ruma Banerjee

Cytochrome P450 (P450, CYP) 4A11 is a human fatty acid  $\omega$ -hydroxylase that catalyzes the oxidation of arachidonic acid to the eicosanoid 20-hydroxyeicosatetraenoic acid (20-HETE), which plays important roles in regulating blood pressure regulation. Variants of P450 4A11 have been associated with high blood pressure and resistance to anti-hypertensive drugs, and 20-HETE has both pro- and antihypertensive properties relating to increased vasoconstriction and natriuresis, respectively. These physiological activities are likely influenced by the redox environment, but the mechanisms are unclear. Here, we found that reducing agents (e.g. dithiothreitol and tris(2-carboxyethyl)phosphine) strongly enhanced the catalytic activity of P450 4A11, but not of 10 other human P450s tested. Conversely, added H<sub>2</sub>O<sub>2</sub> attenuated P450 4A11 catalytic activity. Catalytic roles of five of the potentially eight implicated Cys residues of P450 4A11 were eliminated by site-directed mutagenesis. Using an isotope-coded dimedone/iododimedone-labeling strategy and mass spectrometry of peptides, we demonstrated that the heme–thiolate cysteine (Cys-457) is selectively sulfenylated in an H<sub>2</sub>O<sub>2</sub> concentration-dependent manner. This sulfenylation could be reversed by reducing agents, including dithiothreitol and dithionite. Of note, we observed heme ligand cysteine sulfenylation of P450 4A11 *ex vivo* in kidneys and livers derived from CYP4A11 transgenic mice. We also detected sulfenylation of murine P450 4a12 and 4b1 heme peptides in kidneys. To our knowledge, reversible oxidation of the heme thiolate has not

previously been observed in P450s and may have relevance for 20-HETE–mediated functions.

Human cytochrome P450 (P450 or CYP)<sup>4</sup> enzymes catalyze oxidations of numerous endogenous substrates, including eicosanoids, steroids, and vitamins (1). At least 13 human P450 enzymes (2C8, 2C9, 2J2, 2U1, 4A11, 4F22, 4F12, 4V2, 4F2, 4F3, 4F8, 5A1, and 8A1) utilize fatty acids and/or eicosanoids as substrates (2). P450 4A11 is primarily an  $\omega$ -hydroxylase, with its main endogenous role apparently being the conversion of arachidonic acid to 20-hydroxyeicosatetraenoic acid (20-HETE) (3). P450 4A11 can also catalyze oxidations of other fatty acid substrates, including lauric acid (4).



P450 4A11 is expressed mainly in the liver, kidney, and vasculature (5, 6), and subfamily 4A P450 enzymes have been associated with vascular dysfunction and hypertension in rodent models and humans (7). The P450 4A11 F434S variant has been associated with increased blood pressure in several populations studied (8–13). 20-HETE plays opposing roles, having both pro- and antihypertensive actions by promoting vasoconstriction or natriuresis, respectively (14). 20-HETE has been reported to induce transcription of NADPH oxidase, activating this enzyme complex through protein kinase C (15–18), and has also been reported to increase mitochondrial reactive oxygen species (ROS) production (19). Studies with P450 4A11 transgenic mice have identified P450 4A11 regulation via fasting and growth hormone (20) and shown that 20-HETE and P450 4A11 activity may uncouple the renal renin angiotensin system (21).

This work was supported in part by National Institutes of Health Grants R35 CA090426 (to F. P. G.), R01 GM118122 (to F. P. G.), R01 DK095761 (to A. P.), R01 CA162433 (to A. P.), R01 HD004445 (to E. F. J.), and T32 ES007028 (to M. E. A.); Veterans Affairs Grant I01 BX002025-01 (to A. P.); and National Research Foundation of Korea Grant NRF-2016R1A2B4006978 (to C.-H. Y.). Some of the mass spectrometry work was funded in part by National Institutes of Health Grant P30 CA068485 (Vanderbilt-Ingram Cancer Center Support Grant). The authors declare that they have no conflicts of interest with the contents of this article. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.


This article contains supplemental Figs. S1–S6.

<sup>1</sup> Supported in part by American Heart Association Predoctoral Fellowship PRE33410007.

<sup>2</sup> Recipient of a Veterans Affairs Senior Research Career Scientist award.

<sup>3</sup> To whom correspondence should be addressed: Dept. of Biochemistry, Vanderbilt University School of Medicine, 638B Robinson Research Bldg., 2200 Pierce Ave., Nashville, TN 37232-0146. Tel.: 615-322-2261; Fax: 615-343-0704; E-mail: f.guengerich@vanderbilt.edu.

<sup>4</sup> The abbreviations used are: P450 (or CYP), cytochrome P450; *b*<sub>5</sub>, cytochrome *b*<sub>5</sub>; DLPC, 1- $\alpha$ -1,2-dilauryl-*sn*-glycero-3-phosphocholine; HCD, higher-energy collisional dissociation; HEPPS, 4-(2-hydroxyethyl)-1-piperazinepropanesulfonic acid; 20-HETE, 20-hydroxyeicosatetraenoic acid; ICAT, isotope-coded affinity tagging; ICDID, isotope-coded dimedone/iododimedone; ROS, reactive oxygen species; TCEP, tris(2-carboxyethyl)phosphine; BisTris, 2-[bis(2-hydroxyethyl)amino]-2-(hydroxymethyl)propane-1,3-diol.



**Figure 1. Stimulation of lauric acid  $\omega$ -hydroxylation activity by DTT and TCEP.** P450 4A11 was preincubated with varying concentrations of either DTT (A) or TCEP (B), and rates of lauric acid  $\omega$ -hydroxylation were measured. Error bars, S.D.


ROS, specifically  $H_2O_2$ , have recently become regarded as important secondary signaling molecules (22).  $H_2O_2$  modifies epidermal growth factor receptor signaling (23) and regulates glycolysis through glyceraldehyde-3-phosphate dehydrogenase (24). Common targets of  $H_2O_2$  are protein thiols, which it oxidizes to more reactive species, mainly sulfenic acids (-SOH). This transient posttranslational modification aids in the formation of inter- or intramolecular disulfide bonds, alters cellular signaling, and regulates enzymatic activity (25, 26).

In this study, we noted the stimulation of P450 4A11 activity by thiols and other reducing agents and further examined the ability of P450 4A11 to respond to perturbations in the redox environment *in vitro*. Ten other recombinant human P450s were tested for sensitivity to reductants, and no large changes in activity were noted. Five of the eight possible cysteine (to serine) mutants of P450 4A11 were expressed and were found to be catalytically active, reducing the possibilities for the sensitive thiol. We observed that P450 4A11 is sensitive to oxidation and, interestingly, sulfenic acid formation was able to disrupt binding of Cys-457 to the heme iron and inactivate the enzyme, in a very reversible process. We also detected sulfonylation of P450 4A11 and murine subfamily 4a/b P450 enzymes in kidneys and livers derived from *CYP4A11* transgenic mice, suggesting that changes in the redox state of these enzymes might have relevance to the local production of 20-HETE.

## Results

### Stimulation of P450 4A11 $\omega$ -hydroxylation activity by reducing agents

In previous work, the rates of  $\omega$ -hydroxylation of lauric acid varied considerably, from 9 to 21  $\text{min}^{-1}$ , under varying conditions (4). When P450 4A11 was pretreated with either DTT or tris(2-carboxyethyl)phosphine (TCEP) reagents in our preliminary experiments (Fig. 1),  $\omega$ -hydroxylation activity was routinely increased 2–4-fold. Similar results were found with reduced glutathione (results not shown). The ratio of the two major products, 11- and 12-hydroxylauric acid, remained constant with this activation (results not shown). These results indicated that P450 4A11 has a thiol-dependent redox sensitivity, which was investigated further. Redox-dependent activation was also reflected in the increase in  $k_{\text{cat}}$  values for both the wild-type and F434S (*rs1126742*) (8) variants of P450 4A11 (2.1-fold) (Fig. 2, A and B). The  $K_m$  values with and without



**Figure 2. Stimulation of lauric acid  $\omega$ -hydroxylation activity by DTT.** A, wild-type P450 4A11 (*CYP4A11\*1*); B, F434S variant (*rs1126742*).

DTT remained constant between the wild-type enzyme ( $63 \pm 10$  and  $62 \pm 15 \mu\text{M}$ , respectively) and the F434S variant ( $67 \pm 7$  and  $58 \pm 10 \mu\text{M}$ , respectively) (Fig. 2, A and B). Collectively, these results indicate that both wild-type and F434S variant P450 4A11 are activated in a reducing environment, which may have biological relevance *in vivo*.

Ten other human P450 enzymes were tested for thiol-dependent activation with their relevant substrates (Table 1). The highest stimulation observed among these was P450 2C9, with only a 33% increase. The redox sensitivity of P450 4A11 was unique among human P450 enzymes examined here.

### Oxidative inhibition of P450 4A11

P450 4A11 hydroxylation activity was inhibited by  $H_2O_2$ . This inhibition occurred in a time-dependent manner with an 80% loss in activity occurring within 15 min (Fig. 3), a rate much higher than reported for uncatalyzed sulfonylation of thiols (27). Fifty percent activity loss occurred at a concentration of 140  $\mu\text{M}$   $H_2O_2$  (Fig. 4).

### Site-directed mutagenesis


P450 4A11 encodes eight cysteinyl residues in the translated protein, and five of these cysteines were mutated to serines. Cys-457 corresponds to the proximal heme ligand and could not be changed (28), and neither C347S nor C375S produced protein with the typical P450 difference spectrum (29). Steady-state kinetic assays were done with the remaining five cysteine mutants, both with and without DTT pretreatment (Fig. 5). The response to DTT was qualitatively the same as that of the wild-type P450 4A11 (Fig. 2A), except for C200S (Fig. 5C) and possibly C513S (Fig. 5, A and E), but these analyses did not implicate any of these five cysteines as being involved in the

**Table 1**


Effects of DTT on catalytic activities of P450 4A11 and other human P450s

Position of hydroxylation (OH) or product is indicated.

Human P450	Substrate	Reaction	Catalytic activity		Change
			-DTT	+DTT (1 mM)	
			<i>nmol product/min/nmol P450</i>		%
4A11	Lauric acid	12-OH	9.0 ± 1.1	38 ± 1	+320
2C8	Paclitaxel	6-OH	1.8 ± 0.1	1.9 ± 0.1	+7
2C9	Tolbutamide	1'-OH	1.1 ± 0.1	1.5 ± 0.2	+33
2D6	Bufuralol	4'-OH	2.9 ± 0.1	3.2 ± 0.1	+9
3A4	Nifedipine	Desaturation	2.0 ± 0.6	1.8 ± 0.5	-10
19A1	Testosterone	Estrone formation	10.8 ± 0.2	10.9 ± 0.9	+1
21A2	Progesterone	21-OH	51 ± 10	68 ± 6	+30
2A6	Coumarin	6-OH	NC <sup>a</sup>	NC	-14
1A1	Ethoxyresorufin	(Resorufin)	NC	NC	+8
1A2	Ethoxyresorufin	(Resorufin)	NC	NC	+26
1B1	Ethoxyresorufin	(Resorufin)	NC	NC	-4

<sup>a</sup> NC, assayed using fluorescence methods, but absolute amounts of product not calibrated.

**Figure 3. Kinetics of loss of lauric acid  $\omega$ -hydroxylation activity of P450 4A11 in the presence of  $H_2O_2$ .** P450 4A11 (500 nM) was incubated with 500  $\mu M$   $H_2O_2$  in oxidation buffer (see "Experimental procedures") (pH 8.0) for the indicated times. Residual  $H_2O_2$  was removed by treatment with human erythrocyte catalase (50 units  $ml^{-1}$ ) for 10 min, and lauric acid  $\omega$ -hydroxylation activity was measured in a reconstituted enzyme system. The initial (uninhibited) rate was 26.9 nmol of  $\omega$ -hydroxylation activity lauric acid formed  $min^{-1}$  (nmol of P450) $^{-1}$ . Results are presented as means  $\pm$  S.D. (error bars) of triplicate experiments.



**Figure 4. Loss of P450 4A11 lauric acid  $\omega$ -hydroxylation activity as a function of  $H_2O_2$ .** P450 4A11 (500 nM) was incubated with varying concentrations of  $H_2O_2$  for 15 min at 37 °C in oxidation buffer (pH 8.0). Catalase (10 units  $ml^{-1}$ ) was added to quench the residual  $H_2O_2$  (for 10 min at 25 °C), and the remaining P450 4A11 was reconstituted and used to measure lauric acid  $\omega$ -hydroxylation activity. Results are presented as means  $\pm$  S.D. (error bars) of triplicate experiments. The outer lines indicate 95% confidence intervals.

modulation of hydroxylation activity observed in the wild-type enzyme. The major conclusion was that none of these five cysteines are critical to the normal activity of P450 4A11, leav-

ing only the non-mutated Cys-347, Cys-375, and Cys-457 as candidates for the oxidation-reduction phenomenon.


### Identification of a sulfenic acid

A portion of oxidized P450 4A11 treated with each of several different concentrations of  $H_2O_2$  was treated with  $d_6$ -dime-done (co-incubation) and subsequently counter-alkylated with ( $d_0$ -)iododimedone (30) (Fig. 6). The alkylated protein was digested with trypsin and analyzed by LC-MS/MS (Fig. 7); integrated areas of extracted ion chromatograms for the heavy (sulfenic acid-modified) and light (free thiol) were compared using the program Skyline (31). Sulfenylation of (the heme-thiolate ligand) Cys-457 coincided with the attenuation of enzymatic activity observed with increasing concentrations of  $H_2O_2$  (Fig. 8 and supplemental Figs. S1 and S2). Oxidation of the heme-thiolate ligand would lead to an inability of the heme iron to effectively activate oxygen and carry out catalysis.

This sulfenylation, however, did not exclude the possibility for thiol oxidation to occur in the form of intra- or intermolecular disulfide bonds for other P450 4A11 thiols. An isotope-coded affinity tagging (ICAT) approach was developed using  $d_5/d_0$ -iodoacetanilide (32, 33) (Fig. 6). Briefly, samples were treated with varying concentrations of  $H_2O_2$ , and thiols were then trapped using trichloroacetic acid precipitation (34). Protein was then pelleted by centrifugation, resuspended, and treated with  $d_5$ -iodoacetanilide to alkylate free thiols (35). The protein was then precipitated and resuspended in reducing buffer to reduce disulfide bonds (and any unreacted sulfenic acids) and alkylated with  $d_0$ -iodoacetanilide. Tryptic peptides were analyzed via LC-MS/MS, and the area ratios of alkylated deuterated/non-deuterated thiol-containing peptides were analyzed. This experiment showed no differences in ratios between a reduced P450 4A11 protein control and up to 1 mM  $H_2O_2$  (supplemental Fig. S2). Seven of the eight cysteines in P450 4A11 maintained at least 60% reduction (*i.e.* > 60%  $d_0$  labeling) with only Cys-513, the carboxyl-terminal cysteine, being oxidized further with increasing  $H_2O_2$ .

### Spectral analysis of heme-thiolate oxidation

Spectral properties of P450 4A11 were used to further address the proteomic results (*i.e.* to address the hypothesis that the sulfenic acid moiety disrupts the iron coordination of the heme). TCEP-treated P450 4A11 was treated with  $H_2O_2$ ,



**Figure 5. Lauric acid  $\omega$ -hydroxylation activity of Cys  $\rightarrow$  Ser mutants of P450 4A11.** For experiments done at the same time with wild-type P450 4A11, see Fig. 2A. Assays were done in the absence (■) and presence (●) of 1 mM DTT, as indicated. A, C43S; B, C86S; C, C200S; D, C256S; E, C513S. Error bars, S.D.

reconstituted with NADPH-P450 reductase, deaerated, and placed under an anaerobic atmosphere of CO. Following the addition of NADPH, spectra were recorded for TCEP-reduced (Fig. 9A) and  $\text{H}_2\text{O}_2$ -oxidized (Fig. 9B) P450 4A11. The  $\text{H}_2\text{O}_2$ -oxidized protein showed increased absorbance at 420 nm for the CO-bound form. Sodium dithionite was added to these samples, which increased the absorbance of the oxidized enzyme at 450 nm and decreased the absorbance at 420 nm. NADPH-P450 reductase is able to reduce ferric heme to the ferrous state (allowing CO binding) but cannot reduce the sulfenic acid, leading to an inactive protein due to the loss of the thiolate axial coordination. However, dithionite is able to reduce a sulfenic acid (36), allowing for the reduced thiolate to re-ligand with the heme-iron (Fig. 10). The change in  $A_{450}$  upon the addition of dithionite in Fig. 9B corresponds to an increase of  $\sim 0.3 \mu\text{M}$  P450 ( $\sim 30\%$  total, uncorrected for loss of P450 in the degassing procedure), somewhat less than predicted from the LC-MS labeling study (Fig. 8).

#### Sulfenylation of family 4 P450 enzymes in a CYP4A11 transgenic mouse model

To determine whether this oxidative modification of P450 4A11 occurs *in vivo*, a CYP4A11 transgenic mouse model was used (20). Liver and kidney tissues from four male mice were

harvested, and subcellular fractionation was done immediately. Microsomes were obtained within 3 h of tissue harvesting via differential centrifugation and, as with the recombinant protein, incubated with either buffer,  $d_6$ -dimedone, or  $d_6$ -dimedone supplemented with  $500 \mu\text{M}$   $\text{H}_2\text{O}_2$  (Fig. 6). These labeled samples were then treated with catalase, reduced, counter-alkylated with ( $d_0$ -)iododimmedone, and digested with chymotrypsin. Chymotrypsin was used to produce peptides containing the heme-ligand cysteine unique to both P450s 4A11 and 4A12 in kidneys of male mice (supplemental Fig. S3) (37). The microsomal chymotryptic peptides were analyzed via LC-MS/MS, and the resulting peak area ratios were quantitated. The heme-thiolate Cys-457 of P450 4A11 showed  $\sim 75\%$  dimedone labeling (sulfenylation) in both the dimedone and  $\text{H}_2\text{O}_2$ -supplemented samples in the kidney microsomes of three mice and  $\sim 40\%$  labeling in the liver microsomes (Fig. 11 (A and B) and supplemental Fig. S4). One mouse was considerably younger (age of 6 weeks at time of harvest) than the other three (two of which were 3 months old and one of which was 7 months old), and the expression of P450 4A11 was greatly diminished compared with that in the older mice, as judged by peptide recovery. Interestingly, murine P450s 4A12 (Fig. 11 (C and D) and supplemental Fig. S5) and 4b1 (Fig. 11E and supplemental Fig. S6) also




Figure 6. Scheme for analysis of sulfenic acids and disulfides of P450 4A11.

showed significant sulfenylation of the respective heme–thiol ligands. The younger mouse had consistently lower levels of sulfenylation of the heme-binding peptide for all of the family 4 P450s in the kidneys and lower levels of P450 4a12 in the liver, but the sulfenylation of P450 4A11 in the liver was not different from that of the older mice.

## Discussion


We have shown that H<sub>2</sub>O<sub>2</sub> reacts with the heme–thiolate cysteine of P450 4A11 to form a sulfenic acid and disrupt the iron-sulfur coordination. Five of the eight Cys residues in the protein were shown not to be essential for activity (Fig. 5), and the heme-proximal ligand Cys-457 was identified as the major site of oxidation by modification and proteomic analysis (Figs. 7 and 8). It is well-established that breaking this bond will also convert P450 to an inactive form, cytochrome P420 (38, 39). The accessibility of the heme thiolate ligand has been established in studies with mercurials, as well as the conversion to the inactive cytochrome P420 (40, 41).

The concentration of H<sub>2</sub>O<sub>2</sub> required to inhibit P450 4A11 (Fig. 4) is within a physiological range (42) and was shown to be reversible via reduction by thiols (Fig. 1). P450 enzymes are known to produce H<sub>2</sub>O<sub>2</sub> in conjunction with NADPH-P450 reductase and NADPH, with or without substrate present (43). H<sub>2</sub>O<sub>2</sub> production was measured (43) for a typical reaction containing 0.2 μM P450 4A11, 0.4 μM NADPH-P450 reductase, the

NADPH-generating system, and 100 μM lauric acid and determined to be 5 μM min<sup>-1</sup> (i.e. 25 nmol of H<sub>2</sub>O<sub>2</sub> produced min<sup>-1</sup> (nmol of P450 4A11)<sup>-1</sup>). Typical incubations with lauric acid or arachidonic acid are conducted for 2–3 times this long, and the concentration of H<sub>2</sub>O<sub>2</sub> produced should be negligible in proportion to the amount needed to inhibit the enzyme (Fig. 4).

Thiol activation is common in *in vitro* (25). The activation seen in the case of P450 4A11 was considerably higher than with any other P450s tested (Table 1), indicating that this redox sensitivity is rather unusual among the human P450s tested. Although numerous P450 purification protocols include dithiothreitol or β-mercaptoethanol (44, 45), it is not clear that this is necessary in most cases.

Oxidation of P450 4A11 with H<sub>2</sub>O<sub>2</sub> led to an attenuation of enzymatic activity (Figs. 3 and 4). This loss of activity was correlated with an increased observation of dimedone alkylation (sulfenylation) at Cys-457, the heme–thiolate ligand (Figs. 7 and 8). Sulfenic acid modifications have been directly implicated in the regulation of numerous enzymatic processes, including glyceraldehyde-3-phosphate dehydrogenase, peroxiredoxin, epidermal growth factor receptor, and others (26). However, sulfenic acid formation involving disruption of heme–iron coordination is unprecedented to our knowledge. Choudhury *et al.* (46) mutated the cytochrome *c* peroxidase distal histidine ligand to a cysteine and observed a cysteic acid



**Figure 7. Peptide analysis.** Annotated HCD MS/MS of the heme-thiolate-containing peptide ( $^{456}\text{NCIGK}^{460}$ ) alkylated with  $d_0$ -dimedone (A) or  $d_6$ -dimedone (B).

(cysteine sulfenic acid) in a crystal structure of the cysteine mutant, with a sulfonate oxygen coordinated to the heme. They observed activity, but it was markedly lower than that of the unmodified enzyme. These results were interpreted as the heme iron itself oxidizing the cysteine, as a substrate. This is an appropriate conclusion, in that peroxidases generally have non-Cys heme ligands (47, 48). Nitrile hydratase enzymes are known to coordinate iron or cobalt with both sulfenylated and sulfinylated thiols; additionally, the sulfenic acid is essential for the formation of the carbamate product (49). Our results do not discern whether the sulfenylated thiol is still (weakly) coordinated to the heme or the coordination is completely disrupted in P450 4A11. Dimedone, however, can react with sulfenamides as well as sulfenic acids (50), and such reactions would provide similar results in these experiments as sulfenic acid. If a sulfenamide was indeed the cause of this redox modulation, generally thiol oxidation to sulfenic acid would occur first, followed by subsequent condensation with a backbone nitrogen to form the sulfenamide (50).


ICAT analysis with iodoacetanilide did not provide evidence for a disulfide bond.  $\alpha$ -Haloketones react with sulfenic acids to form sulfoxides (35), so these peptides would not be quantified

in a direct analysis between  $d_0/d_5$ -alkylated peptides because the  $m/z$  would increase by 16, the mass of oxygen. Inaccuracy could also be due to further di- and trioxidation ( $-\text{SO}_2^-$  and  $-\text{SO}_3^-$ , respectively) of cysteines. Cys-513 appeared to be the only thiol oxidized to a large extent in our analysis, although the exact nature is unknown. Additionally, Cys-347 and Cys-375 appear to have proximity to each other in the homology model (Fig. 12). The inability to express the mutated forms of these two cysteines indicates that they are probably important for structural and/or conformational integrity, but our ICAT analysis does not indicate that either thiol is oxidized.

Taken together, the mutant analysis, dimedone labeling, and ICAT labeling methods show that cysteines other than Cys-457 are oxidized in P450 4A11 but do not appear to directly inactivate the protein or are correlated with the loss of activity. The oxidation or mutation of these ancillary cysteines could produce slight conformational changes, but these changes would not produce the spectral change at 450 nm that sulfenylation of Cys-457 does.

Detection of sulfenylation in murine kidneys and livers provides a physiological context for this modification. The high percentage of dimedone alkylation seen in the P450 4A11, 4a12,

## P450 4A11 sulfenic acid and inhibition



**Figure 8. Formation of a sulfenic acid in Cys-457 (heme thiol group) as a function of H<sub>2</sub>O<sub>2</sub> concentration.** P450 4A11 samples were labeled with *d*<sub>6</sub>-dimedone and counter-alkylated with *d*<sub>0</sub>-iododimedone at varying concentrations of H<sub>2</sub>O<sub>2</sub>. Labeled protein was then subject to trypsin digestion and LC-MS/MS analysis. Masses corresponding to Cys-457 deuterated and non-deuterated peptides were extracted, and the resulting areas were integrated using Skyline software. A, bar graphs of comparisons of peak areas for CySH peptide (red) and CyS-OH peptide (blue); raw peaks for CySH peptide (red) and CyS-OH peptide (blue) (not normalized in each case).


and 4b1 heme peptides was surprising in that this would imply that a large percentage of the family 4 P450 enzymes is constitutively inactive in the kidney. One possible explanation could be that, because 20-HETE is a very potent vasoconstrictor with submicromolar activity (52, 53), these enzymes are very tightly regulated, and sulfenylated enzymes could act as a reserve mechanism. Conversely, if an increase in vascular tone is required quickly, family 4 P450 enzymes could be reduced quickly and be available for production of 20-HETE. P450 4A11 sulfenylation was observed to a lesser degree in the liver. This may be due to the larger reducing potential in glutathione stores the liver has compared with the kidney (54).

One unique feature of subfamily 4A P450 enzymes is the covalent binding of the heme prosthetic group to the enzyme through a conserved glutamic acid residue (55, 56). This unique feature may allow for easier recoordination of the reduced thiol with an immobilized heme iron. In recombinant P450 4A11, it is reported that ~25% of the enzyme has covalently bound heme (56), but the fraction has not been determined in human samples. Rodent subfamily 4A P450 enzymes have higher percentages of heme covalently bound to the enzyme (56). LeBrun *et al.* (56) suggest that this covalent binding may contribute to differences in substrate binding rates and enzymatic regioselectivity.

A recent crystal structure of recombinant rabbit P450 4B1 shows complete adduction of the heme through a bond

between a heme methyl group and Glu-310 (analogous to Glu-321 in P450 4A11) (57). In examining the alignment of mouse P450 4b1 and rabbit P450 4B1 (UniProt), these two enzymes share 86% identity and 95% similarity. A modeled structure shows a relatively open conformation on the proximal side of the protein (Fig. 12). Cysteines that were mutated in this study are located in the peripheries of the protein, away from the proposed active site, and probably do not influence enzyme function.

Disruption of the iron-sulfur coordination would alter the absorbance properties of P450 4A11 (Fig. 10). Under an anaerobic CO atmosphere, NADPH-P450 reductase can reduce ferric heme to its ferrous state, allowing CO to bind. This CO-bound state has absorbance with  $\lambda_{\max}$  at 450 nm if the heme-thiolate ligand is intact. When this coordination is disrupted (via sulfenylation in this case), the CO-binding spectrum is shifted to a  $\lambda_{\max}$  at 420 nm (Figs. 9 and 10). Interestingly, the addition of dithionite after reduction with NADPH-P450 oxidoreductase reduces the sulfenic acid (36) and allows for recoordination of the thiolate-heme complex. The observation of a sulfenylated heme-thiolate ligand has probably been overlooked previously because of the common laboratory practice of determining P450 concentration using dithionite as the reducing agent for obtaining P450 difference spectra.



**Figure 9.** Reduction of P450 4A11 by NADPH-P450 reductase and sodium dithionite in the presence of CO. Reduced protein (A) and protein oxidized with 500  $\mu\text{M}$   $\text{H}_2\text{O}_2$  (B) was deaerated and placed under an anaerobic CO atmosphere. NADPH was then added, and absorbance spectra were recorded (blue). Dithionite was then added (red).

In summary, P450 4A11 seems to show a unique activation under reducing conditions compared with other P450 enzymes tested. Conversely,  $\text{H}_2\text{O}_2$  inhibits the enzymatic activity of the enzyme. Sulfenic acid formation of the heme thiolate ligand was detected by labeling and LC-MS analysis (Figs. 7 and 8) and was verified spectrally (Fig. 9). The physiological relevance of the modification was demonstrated with the identification of sulfenylated P450s in freshly isolated murine kidneys and livers. This modification is a potentially important observation that may have implications in other P450s, as shown by our results with the mouse P450 4a and 4b enzymes. Sulfenylation could provide for biological regulation of P450 4A11 and its production of the potent vasoconstrictor 20-HETE. As mentioned previously, 20-HETE has been shown to induce ROS formation as well as to play an important role in blood pressure control, which is known to be mediated by ROS production (58). The extent of sulfenylation of 4A/a P450 enzymes in tissues may provide a mechanism to reduce the production of 20-HETE.

## Experimental procedures

### Chemicals

[1- $^{14}\text{C}$ ]Lauric acid was obtained from American Research Chemicals (St. Louis, MO). Lauric acid, TCEP,  $\text{H}_2\text{O}_2$  (30%, w/v), paclitaxel, tolbutamide, bufuralol, nifedipine, testosterone, progesterone, coumarin, and ethoxyresorufin were obtained from Sigma-Aldrich.

### Chemical synthesis

**Iododimedone**—Iododimedone was prepared from dimedone (4-mmol scale) by iodination with *N*-iodosuccinimide (59). Yield 48%, mp 145–146 °C; high-resolution mass spectrometry for  $\text{C}_8\text{H}_{12}\text{O}_2\text{I}$   $m/z$  266.9882 ( $\text{MH}^+$ ), found 266.9881 ( $\Delta$  0.4 ppm);  $^1\text{H}$  NMR (400 MHz,  $\text{CDCl}_3$ )  $\delta$  1.04 (s, 6H,  $(\text{CH}_3)_2$ ), 2.50 (d (splitting due to I), 4H,  $\text{CH}_2$ ), 6.35 (s, 1H, CHI) (literature mp 155 °C (60)).

***d*<sub>6</sub>-Dimedone**—A modification of the basic procedure of Seo and Carroll (30) was used. Diethyl malonate and mesityl-*d*<sub>10</sub>-oxide were condensed in an ethanolic solution of  $\text{NaOC}_2\text{H}_5$  under reflux, followed by decarboxylation with NaOH under reflux. Following neutralization, the filtrate was collected and extracted into ethyl acetate. The product was concentrated by partial removal of solvent *in vacuo* and trituration with hexanes to yield crystalline *d*<sub>6</sub>-dimedone in 85% yield. mp 147–148 °C; high-resolution mass spectrometry for  $\text{C}_8\text{H}_7\text{D}_6\text{O}_2$   $m/z$  147.1292 ( $\text{MH}^+$ ), obs 147.1284 ( $\Delta$  5.4 ppm);  $^1\text{H}$  NMR (400 MHz,  $\text{CDCl}_3$ )  $\delta$  2.52 (s, 5H,  $-\text{CH}_2-$ ), 3.33 (s, 2H,  $\text{CO}-\text{CH}_2-\text{CO}$ ) (61) (literature mp 145–147 °C (61)).

***d*<sub>o</sub>-Iodoacetanilide**—Iodoacetanilide was prepared from iodoacetic acid (2.53 mmol) and aniline (2.53 mmol) by amide coupling with dicyclohexylcarbodiimide (2.53 mmol) (62). Yield 70%,  $^1\text{H}$  NMR (600 MHz, acetone-*d*<sub>6</sub>)  $\delta$  9.51 (bs, 1H, NH) 7.64 (d, 2H, *o*-Ar), 7.31 (t, 2H, *m*-Ar), 7.02 (t, 1H, *p*-Ar), 3.90 (s, 2H,  $\text{CH}_2\text{I}$ ),  $^{13}\text{C}$  NMR (150 MHz, acetone-*d*<sub>6</sub>) 167.0, 140.1, 129.7, 124.6, 120.0, 0.72.

***d*<sub>5</sub>-Iodoacetanilide**—*d*<sub>5</sub>-Iodoacetanilide was prepared from iodoacetic acid (2.53 mmol) and *d*<sub>5</sub>-aniline (2.53 mmol) by amide coupling with dicyclohexylcarbodiimide (2.53 mmol) (62). Yield 89%,  $^1\text{H}$  NMR (600 MHz, acetone-*d*<sub>6</sub>)  $\delta$  9.53 (bs, 1H, NH), 3.90 (s, 2H,  $\text{CH}_2\text{I}$ ),  $^{13}\text{C}$  NMR (150 MHz, acetone-*d*<sub>6</sub>) 167.0, 139.8, 129.1, 124.1, 119.6, 0.75.

### Enzymes


Human P450 4A11 (wild-type and F434S, C52S, C85S, C199S, C255S, and C512S mutants) was expressed and purified as described previously (4, 63). *Escherichia coli* recombinant rat NADPH-P450 reductase and human liver cytochrome *b*<sub>5</sub> (*b*<sub>5</sub>) were prepared as described by Hanna *et al.* (64) and Guengerich (65), respectively.

### Tissue samples


All experiments using mice were conducted with approved protocols by the Institutional Animal Care and Use Committee of Vanderbilt University and in accordance with the National Institutes of Health Guide for the Care and Use of Laboratory animals. 129/Sv mice carrying one copy of the human cytochrome P450 4A11 gene (*CYP4A11*) (under control of its native promoter, generated as described previously (21)) were provided a normal chow diet (Laboratory Rodent 5001, Purina, St. Louis, MO) with free access to water and were housed in an Association for the Assessment and Accreditation of Laboratory Animal Care (AAALAC)-accredited, temperature-controlled facility with a 12-h light/dark cycle. All studies were conducted in mice 6–28 weeks of age. *CYP4A11* transgenic mice were crossed with pure Sv129 wild-type mice, and offspring were genotyped for the presence of a single copy of the



## P450 4A11 sulfenic acid and inhibition



**Figure 10. Scheme of Cys-457 sulfenic acid formation and reduction in P450 4A11.** In the presence of  $\text{H}_2\text{O}_2$ , the heme–thiolate ligand becomes oxidized and loses its coordination with the heme iron. The sulfenic acid is not reduced by NADPH-P450 reductase but can be reduced by dithionite, reforming the heme coordination.




**Figure 11. Analysis of human and mouse P450 peptides in tg4A11 mice.** Microsomes (prepared from kidney and liver tissues of *CYP4A11* transgenic mice within 3 h after sacrifice) were treated with either vehicle (control),  $d_6$ -dimezone, or  $d_6$ -dimezone supplemented with  $500 \mu\text{M}$   $\text{H}_2\text{O}_2$ . Integrated areas for ions corresponding to peptides of the heme–thiolate for P450s 4A11 (A and B), 4a12 (C and D), and 4b1 (E) were compared and reported as percent sulfenylation (percent sulfenylation = area of  $d_6$ -dimezone-labeled peptide/ (area of  $d_6$ -dimezone-labeled peptide plus area of  $d_0$ -dimezone-labeled peptide)). See “Experimental procedures” and Fig. 6. The  $p$  values using Student’s  $t$  test comparing control- and dimezone-treated tissue were all  $< 0.03$  except for the P450 4a12 kidney (C) ( $p = 0.058$ ). The mouse indicated with the inverted triangle was 6 weeks old, much younger than the other three animals (two were 3 months old, and one was 7 months old).

human *CYP411* gene as described previously (21). Organs were collected from male transgenic mice immediately after sacrifice and used for microsomal preparations as described below.

### Site-directed mutagenesis

P450 4A11 was subcloned into a pBlueScript vector to perform site-directed mutagenesis. Residues from each site were



**Figure 12. Homology model of P450 4A11 based on crystal structure of rabbit P450 4B1 (57).** A, all Cys residues are shown; B, positions of Asn-456, Lys-460, and Phe-462 near the heme and Cys-457 (yellow sphere).

converted to serine by using the QuikChange II site-directed mutagenesis kit (Agilent Technologies). The resulting plasmids were sequenced to confirm successful mutation and subcloned into a pCW expression vector.

### Enzymatic assays

Assays were done as described previously (4) with minor changes. Typical incubations included  $0.2 \mu\text{M}$  P450 4A11,  $0.4 \mu\text{M}$  NADPH-P450 reductase,  $0.4 \mu\text{M}$   $b_5$ ,  $150 \mu\text{M}$  *L*- $\alpha$ -dilauroyl-*sn*-glycero-3-phosphocholine (DLPC; Sigma-Aldrich),  $100 \text{ mM}$  potassium phosphate buffer (pH 7.4), and the indicated concentration of lauric acid ( $[1-^{14}\text{C}]$ lauric acid, usually added as an aqueous  $10 \text{ mM}$  solution of sodium laurate) in a final volume of  $0.25 \text{ ml}$ .  $b_5$  was included because it stimulates the catalytic activity (4). Following temperature equilibration to  $37^\circ\text{C}$  for 5 min, reactions were initiated by the addition of an NADPH-regenerating system consisting of  $0.5 \text{ mM}$   $\text{NADP}^+$ ,  $10 \text{ mM}$  glucose 6-phosphate, and  $1 \text{ IU ml}^{-1}$  yeast glucose 6-phosphate

dehydrogenase (66). Reactions generally proceeded at 37 °C for 2 min and were terminated with 1.0 ml of ethyl acetate containing 0.1% CH<sub>3</sub>CO<sub>2</sub>H (v/v), and, following mixing with a vortex device, the mixtures were centrifuged (10<sup>3</sup> × *g* for 10 min). A 0.8-ml aliquot of the ethyl acetate layer (upper phase) was transferred to a clean tube, and the solvent was removed under an N<sub>2</sub> stream.

The dried extracts were dissolved in 200 μl of a 1:1 mixture of H<sub>2</sub>O/CH<sub>3</sub>CN containing 0.1% CH<sub>3</sub>CO<sub>2</sub>H (v/v) and 10 μM butylated hydroxytoluene, and aliquots were analyzed on a reversed-phase (octadecylsilane, C<sub>18</sub>) HPLC column (5 μM, 2.1 × 100 mm (Waters, Milford, MA)) coupled with a radioactivity detector (β-RAM, IN/US Systems, Tampa, FL). Reaction products and substrate were eluted at a flow rate of 0.6 ml min<sup>-1</sup> using an increasing linear gradient of CH<sub>3</sub>CN (including 0.1% (v/v) HCO<sub>2</sub>H) from 35 to 95% (v/v) over 30 min.

Assays with P450s other than P450 4A11 were performed as described previously, with the modification of either preincubation with DTT (1 mM) for 10 min or not (the DTT remained in the reactions): P450 2C8-paclitaxel as substrate (67), P450 2C9-tolbutamide as substrate (68), P450 2D6-bufuralol as substrate (69), P450 3A4-nifedipine as substrate (70), P450 19A1-testosterone as substrate (71), P450 21A2-progesterone as substrate (72), P450 2A6-coumarin as substrate (73), and P450s 1B1-, 1A1-, and 1A2-7-ethoxyresorufin as substrate (74).

#### Protein oxidation

Purified recombinant P450 4A11 (0.4 ml of a 10 μM stock solution, stored at -80 °C in 50 mM potassium phosphate buffer (pH 7.4) containing 20% glycerol, 1 mM DTT, and 0.1 mM EDTA) was thawed on ice and reduced for 30 min by the addition of 1 mM TCEP at 4 °C. A Zeba spin desalting column (Thermo) pre-equilibrated with "oxidation buffer" (100 mM potassium phosphate buffer (pH 7.4) containing 0.1 mM EDTA and sparged with argon) was used to remove reducing agents. Reduced protein was then diluted to a concentration of 500 nM using oxidation buffer. Aliquots were treated with varying amounts of H<sub>2</sub>O<sub>2</sub> or TCEP. Aliquots for the activity assay (175 pmol; described above) were incubated with H<sub>2</sub>O<sub>2</sub> or TCEP for 15 min at 37 °C. Human erythrocyte catalase (10 units; Sigma, catalogue no. C3556) was added, and incubations proceeded at 23 °C for 5 min to remove H<sub>2</sub>O<sub>2</sub>. These samples were used to measure lauric acid ω-hydroxylation activity as described above.

#### Isotope-coded dimedone/iododimedone (ICDID) labeling of recombinant P450 4A11

Additional aliquots of oxidized protein (from above; 100 pmol) were incubated with 5 mM *d*<sub>6</sub>-dimedone (from a 50 mM stock suspended in 100 mM HEPPS (pH 8.0) containing 5% NaCl (w/v)) for 2 h at 37 °C. Trichloroacetic acid was then added to a final concentration of 10% (v/v), and the samples were incubated on ice for 15 min. The enzymes in the samples were pelleted by centrifugation (12,000 × *g*, 15 min, 4 °C). The supernatant was removed from each sample, and the pellet was washed with ice-cold CH<sub>3</sub>CN. The pellet was resuspended in 20 μl of 100 mM HEPPS buffer (pH 8.0) containing 2% (w/v) SDS

and 1 mM TCEP, and reduction proceeded for 30 min at 37 °C. (*d*<sub>0</sub>-)Iododimedone (100 mM stock, in acetone) was added to a final concentration of 10 mM, and incubation was done at 23 °C in the dark for 30 min. Samples were subjected to SDS-PAGE (10% BisTris, NuPAGE, Invitrogen) separation and stained with SimplyBlue SafeStain (Invitrogen). The *M*<sub>r</sub> region corresponding to P450 4A11 was excised, digested with trypsin (8 ng/μl) for 16 h in 25 mM NH<sub>4</sub>HCO<sub>3</sub> (pH 7.8) at 37 °C, and subjected to LC-MS/MS analysis.

#### ICAT labeling of recombinant P450 4A11

Additional aliquots of reduced, buffer-exchanged protein (from above; 100 pmol) were incubated with H<sub>2</sub>O<sub>2</sub> or TCEP for 15 min. Human erythrocyte catalase (10 units) was added, and incubations proceeded at 23 °C for 5 min to remove H<sub>2</sub>O<sub>2</sub>. Trichloroacetic acid was then added to a final concentration of 10% (v/v), and the samples were incubated on ice for 15 min. The enzymes in the samples were pelleted by centrifugation (12,000 × *g*, 15 min, 4 °C). The supernatant was removed from each sample, and the pellet was washed with ice-cold CH<sub>3</sub>CN. The pellet was resuspended in 50 μl of 100 mM HEPPS buffer (pH 8.0) containing 2% (w/v) SDS and 10 mM *d*<sub>5</sub>-iodoacetanilide, and alkylation proceeded for 30 min at 23 °C, with shaking in the dark. Protein was precipitated again using the same method as above to remove heavy reagent. The pellet was resuspended in 20 μl of 100 mM HEPPS buffer (pH 8.0) containing 2% (w/v) SDS and 1 mM TCEP, and reduction proceeded for 30 min at 50 °C. *d*<sub>0</sub>-Iodoacetanilide (100 mM, in acetone) was added to a final concentration of 10 mM, and incubation was done at 23 °C in the dark for 30 min, with shaking. Samples were subjected to SDS-PAGE (10% BisTris, NuPAGE, Invitrogen) separation and stained with SimplyBlue SafeStain (Invitrogen). The *M*<sub>r</sub> region corresponding to P450 4A11 was excised, digested with trypsin (8 ng/μl) for 16 h in 25 mM NH<sub>4</sub>HCO<sub>3</sub> (pH 7.8) at 37 °C, and subjected to LC-MS/MS analysis.

#### Preparation of microsomes

Microsomes from freshly excised tissues were prepared with slight modifications of published methods (66). For ICDID labeling studies, the buffer (0.10 M Tris acetate (pH 7.4) containing 0.10 M KCl, 1.0 mM EDTA, and 20 μM butylated hydroxytoluene) was sparged with argon before use. Tissue samples were homogenized using a Teflon-glass Potter-Elvehjem device and centrifuged at 10<sup>4</sup> × *g* for 20 min. at 4 °C. Homogenates were then treated as described (66), and the final microsomal pellets were resuspended in 100 mM HEPPS buffer (pH 8.0) containing 1 mM EDTA. Aliquots of these samples were incubated with vehicle, 10 mM *d*<sub>6</sub>-dimedone, or 10 mM *d*<sub>6</sub>-dimedone plus 500 μM H<sub>2</sub>O<sub>2</sub> for 1 h at 37 °C. Catalase (10 units) was added to each and incubated at 25 °C for 10 min to remove excess H<sub>2</sub>O<sub>2</sub>. Aliquots were reduced with 1 mM TCEP at 37 °C for 30 min, and 10 mM (*d*<sub>0</sub>-)iododimedone was then added. The protein concentrations of microsomes were estimated using a bicinchoninic acid (BCA) assay (Pierce). Alkylated microsomes (60 μg of protein) were subjected to SDS-PAGE (10% gel; see above), and the P450 region (*M*<sub>r</sub> 45–60 kDa) was excised, digested with chymotrypsin (8 ng/μl) for 4 h

## P450 4A11 sulfenic acid and inhibition

in 25 mM  $\text{NH}_4\text{HCO}_3$  (pH 8.0) at 25 °C, and subjected to LC-MS/MS analysis as described below.

### LC-MS/MS analysis

Extracted peptides were analyzed on a nanoLC Ultra system (Eksigent Technologies, Dublin, CA) interfaced with a LTQ Orbitrap XL mass spectrometer (Thermo Scientific, San Jose, CA). Approximately 5 pmol of peptides was reconstituted in 0.1%  $\text{HCO}_2\text{H}$  (v/v) and pressure-loaded ( $1.5 \mu\text{l min}^{-1}$ ) onto a 360- $\mu\text{m}$  outer diameter  $\times$  100- $\mu\text{m}$  inner diameter microcapillary analytical column packed with Jupiter octadecylsilane (C18) (3  $\mu\text{m}$ , 300 Å; Phenomenex) and equipped with an integrated electrospray emitter tip. Peptides were then separated with a linear gradient formed with 0.1%  $\text{HCO}_2\text{H}$  in  $\text{H}_2\text{O}$  (solvent A) and 0.1%  $\text{HCO}_2\text{H}$  in  $\text{CH}_3\text{CN}$  (solvent B) (all v/v) by increasing from 2 to 45% B (v/v) over a period of 0–45 min at a flow rate of  $500 \text{ nl min}^{-1}$ . The spray voltage was set to 2.0 kV, and the heated capillary temperature was set to 200 °C. Higher-energy collisional dissociation (HCD) MS/MS spectra were recorded in the data-dependent mode using a top-2 method with an inclusion list containing  $m/z$  values corresponding to P450 4A11 tryptic peptides, which included both  $d_6$ - and  $d_0$ -dimedonylated cysteines, determined *in silico* with Skyline software (75). MS1 spectra were measured with a resolution of 70,000, an AGC target of  $1\text{e}6$ , and a mass range from  $m/z$  300 to 1,500. HCD MS/MS spectra were acquired with a resolution of 7,500, an AGC target of  $1\text{e}5$ , and a normalized collision energy of 35. Peptide  $m/z$  values that triggered MS/MS scans were dynamically excluded from further MS/MS scans for 20 s, with a repeat count of 1.

### Peptide data analysis

Raw data files were analyzed using MyriMatch software (76) against a decoy protein database consisting of a forward and reversed human UniProt/SwissProt database (version 20160620). Precursor ion mass tolerance was set at 10 ppm, and the fragmentation tolerance was 20 ppm for the database search. Methionine oxidation (15.9949 Da, dynamic) and cysteine modifications by  $d_6$ - and  $d_0$ -dimedone (144.1057 and 138.0681 Da, respectively, static) were searched separately as modifications. The maximum  $Q$  values of peptide spectrum matches were adjusted to achieve either a peptide or a protein false-discovery rate  $\leq 5\%$ , using IDPicker software (version 3.1.642.0) (77). A spectral library of peptides was then created with IDPicker and loaded into Skyline software for confident identification of precursors pertaining to cysteine-containing peptides. MS<sup>1</sup> precursor quantitation was performed as described previously (31). For each peptide analyzed, integral areas for M and M + 1 isotopes were used for relative quantitation.

### Spectroscopy

P450 4A11 was oxidized with  $\text{H}_2\text{O}_2$  as above, but the procedure was adapted slightly for spectroscopic assays. The enzyme was diluted with oxidation buffer to 1  $\mu\text{M}$  before the introduction of 1 mM TCEP or 500  $\mu\text{M}$   $\text{H}_2\text{O}_2$ . After oxidation, 30 units catalase was added, and the sample was incubated at 23 °C for 5 min. To this solution, final concentrations of 1  $\mu\text{M}$  NADPH-

P450 reductase, 150  $\mu\text{M}$  DLPC, and 0.1 unit/ml protocatechuate dioxygenase (Sigma) were added to an anaerobic cuvette, with NADPH (300 nmol, aqueous) in a side arm of the cuvette. Samples were degassed, 20  $\mu\text{M}$  3,4-dihydroxybenzoate (Sigma; substrate for protocatechuate dioxygenase) was added to remove oxygen (78), and samples were further degassed using a manifold attached to both vacuum and purified argon (51, 79) and placed under an anaerobic CO atmosphere. The valves of the cuvettes were sealed, and multiple UV-visible absorbance spectra were recorded using an OLIS/Hewlett Packard 8452 diode array spectrophotometer (On-Line Instrument Systems, Bogart, GA). Spectra were collected from 380 to 600 nm before and after the addition of NADPH/sodium dithionite.

---

*Author contributions*—M. E. A. synthesized  $d_0$ - and  $d_6$ -iodoacetanilide and did the dimedone and iodoacetanilide labeling experiments, LC-MS assays, spectroscopic anaerobic reduction assays, and assays of catalytic activity and analyzed results. D. K. did the site-directed mutagenesis studies. F. P. G. synthesized  $d_6$ -dimedone and ( $d_0$ -)iododimedone. L. D. N., D. K., and F. P. G. did the catalytic assays with human P450s (other than P450 4A11). C.-H. Y. did the preliminary thiol activation assays. Ü. S., E. F. J., and A. P. developed and raised the transgenic P450 4A11 mice. M. E. A. and F. P. G. wrote most of the manuscript. F. P. G. oversaw the project. All authors contributed to the conclusions.

---

*Acknowledgments*—We thank the Vanderbilt Proteomics Core for running some of the LC-MS/MS samples and K. Trisler for assistance in preparation of the manuscript.

---

### References

- Ortiz de Montellano, P. R. (ed) (2015) *Cytochrome P450: Structure, Mechanism, and Biochemistry*, 4th Ed., Springer, New York
- Guengerich, F. P. (2015) Human cytochrome P450 enzymes. in *Cytochrome P450: Structure, Mechanism, and Biochemistry*, 4th Ed. (Ortiz de Montellano, P. R., ed) pp. 523–785, Springer, New York
- Capdevila, J. H., Wang, W., and Falck, J. R. (2015) Arachidonic acid monooxygenase: genetic and biochemical approaches to physiological/pathophysiological relevance. *Prostaglandins Other Lipid Mediat.* **120**, 40–49
- Kim, D., Cha, G. S., Nagy, L. D., Yun, C.-H., and Guengerich, F. P. (2014) Kinetic analysis of lauric acid hydroxylation by human cytochrome P450 4A11. *Biochemistry* **53**, 6161–6172
- Lasker, J. M., Chen, W. B., Wolf, I., Bloswick, B. P., Wilson, P. D., and Powell, P. K. (2000) Formation of 20-hydroxyeicosatetraenoic acid, a vasoactive and natriuretic eicosanoid, in human kidney: role of Cyp4F2 and Cyp4A11. *J. Biol. Chem.* **275**, 4118–4126
- Wu, C. C., and Schwartzman, M. L. (2011) The role of 20-HETE in androgen-mediated hypertension. *Prostaglandins Other Lipid Mediat.* **96**, 45–53
- Garcia, V., and Schwartzman, M. L. (2017) Recent developments on the vascular effects of 20-hydroxyeicosatetraenoic acid. *Curr. Opin. Nephrol. Hypertens.* **26**, 74–82
- Gainer, J. V., Bellamine, A., Dawson, E. P., Womble, K. E., Grant, S. W., Wang, Y., Cupples, L. A., Guo, C. Y., Demissie, S., O'Donnell, C. J., Brown, N. J., Waterman, M. R., and Capdevila, J. H. (2005) Functional variant of CYP4A11 20-hydroxyeicosatetraenoic acid synthase is associated with essential hypertension. *Circulation* **111**, 63–69
- Mayer, B., Lieb, W., Götz, A., König, I. R., Aherrahrou, Z., Thiemi, G., Holmer, S., Hengstenberg, C., Doering, A., Loewel, H., Hense, H. W., Schunkert, H., and Erdmann, J. (2005) Association of the T8590C polymorphism of CYP4A11 with hypertension in the MONICA Augsburg echocardiographic substudy. *Hypertension* **46**, 766–771

10. Gainer, J. V., Lipkowitz, M. S., Yu, C., Waterman, M. R., Dawson, E. P., Capdevila, J. H., and Brown, N. J., and AASK Study Group (2008) Association of a CYP4A11 variant and blood pressure in black men. *J. Am. Soc. Nephrol.* **19**, 1606–1612
11. Laffer, C. L., Gainer, J. V., Waterman, M. R., Capdevila, J. H., Laniado-Schwartzman, M., Nasjletti, A., Brown, N. J., and Eljovich, F. (2008) The T8590C polymorphism of CYP4A11 and 20-hydroxyeicosatetraenoic acid in essential hypertension. *Hypertension* **51**, 767–772
12. Zhang, R., Lu, J., Hu, C., Wang, C., Yu, W., Ma, X., Bao, Y., Xiang, K., Guan, Y., and Jia, W. (2011) A common polymorphism of CYP4A11 is associated with blood pressure in a Chinese population. *Hypertens. Res.* **34**, 645–648
13. Williams, J. S., Hopkins, P. N., Jeunemaitre, X., and Brown, N. J. (2011) CYP4A11 T8590C polymorphism, salt-sensitive hypertension, and renal blood flow. *J. Hypertens.* **29**, 1913–1918
14. Wu, C. C., Gupta, T., Garcia, V., Ding, Y., and Schwartzman, M. L. (2014) 20-HETE and blood pressure regulation: clinical implications. *Cardiol. Rev.* **22**, 1–12
15. Bodiga, S., Gruenloh, S. K., Gao, Y., Manthali, V. L., Dubasi, N., Falck, J. R., Medhora, M., and Jacobs, E. R. (2010) 20-HETE-induced nitric oxide production in pulmonary artery endothelial cells is mediated by NADPH oxidase, H<sub>2</sub>O<sub>2</sub>, and PI<sub>3</sub>-kinase/Akt. *Am. J. Physiol. Lung Cell. Mol. Physiol.* **298**, L564–L574
16. Cheng, J., Wu, C. C., Gotlinger, K. H., Zhang, F., Falck, J. R., Narsimhaswamy, D., and Schwartzman, M. L. (2010) 20-Hydroxy-5,8,11,14-eicosatetraenoic acid mediates endothelial dysfunction via I<sub>k</sub>B kinase-dependent endothelial nitric-oxide synthase uncoupling. *J. Pharmacol. Exp. Ther.* **332**, 57–65
17. Han, Y., Zhao, H., Tang, H., Li, X., Tan, J., Zeng, Q., and Sun, C. (2013) 20-Hydroxyeicosatetraenoic acid mediates isolated heart ischemia/reperfusion injury by increasing NADPH oxidase-derived reactive oxygen species production. *Circ. J.* **77**, 1807–1816
18. Zeng, Q., Han, Y., Bao, Y., Li, W., Li, X., Shen, X., Wang, X., Yao, F., O'Rourke, S. T., and Sun, C. (2010) 20-HETE increases NADPH oxidase-derived ROS production and stimulates the L-type Ca<sup>2+</sup> channel via a PKC-dependent mechanism in cardiomyocytes. *Am. J. Physiol. Heart Circ. Physiol.* **299**, H1109–H1117
19. Lakhkar, A., Dhagia, V., Joshi, S. R., Gotlinger, K., Patel, D., Sun, D., Wolin, M. S., Schwartzman, M. L., and Gupte, S. A. (2016) 20-HETE-induced mitochondrial superoxide production and inflammatory phenotype in vascular smooth muscle is prevented by glucose-6-phosphate dehydrogenase inhibition. *Am. J. Physiol. Heart Circ. Physiol.* **310**, H1107–H1117
20. Savas, U., Machemer, D. E., Hsu, M. H., Gaynor, P., Lasker, J. M., Tukey, R. H., and Johnson, E. F. (2009) Opposing roles of peroxisome proliferator-activated receptor  $\alpha$  and growth hormone in the regulation of CYP4A11 expression in a transgenic mouse model. *J. Biol. Chem.* **284**, 16541–16552
21. Savas, Ü., Wei, S., Hsu, M. H., Falck, J. R., Guengerich, F. P., Capdevila, J. H., and Johnson, E. F. (2016) 20-Hydroxyeicosatetraenoic acid (HETE)-dependent hypertension in human cytochrome P450 (CYP) 4A11 transgenic mice: Normalization of blood pressure by sodium restriction, hydrochlorothiazide, or blockade of the type 1 angiotensin II receptor. *J. Biol. Chem.* **291**, 16904–16919
22. Leichert, L. I., and Dick, T. P. (2015) Incidence and physiological relevance of protein thiol switches. *Biol. Chem.* **396**, 389–399
23. Paulsen, C. E., Truong, T. H., Garcia, F. J., Homann, A., Gupta, V., Leonard, S. E., and Carroll, K. S. (2011) Peroxide-dependent sulfenylation of the EGFR catalytic site enhances kinase activity. *Nat. Chem. Biol.* **8**, 57–64
24. Little, C., and O'Brien, P. J. (1969) Mechanism of peroxide-inactivation of the sulphhydryl enzyme glyceraldehyde-3-phosphate dehydrogenase. *Eur. J. Biochem.* **10**, 533–538
25. Anfinsen, C. B., and Haber, E. (1961) Studies on the reduction and reformation of protein disulfide bonds. *J. Biol. Chem.* **236**, 1361–1363
26. Devarie-Baez, N. O., Silva Lopez, E. I., and Furdui, C. M. (2016) Biological chemistry and functionality of protein sulfenic acids and related thiol modifications. *Free Radic. Res.* **50**, 172–194
27. Winterbourn, C. C., and Hampton, M. B. (2008) Thiol chemistry and specificity in redox signaling. *Free Radic. Biol. Med.* **45**, 549–561
28. Poulos, T. L., and Johnson, E. F. (2015) Structures of cytochrome P450 enzymes. in *Cytochrome P450: Structure, Function, and Biochemistry*, 4th Ed. (Ortiz de Montellano, P. R., ed) pp. 3–32, Springer, New York
29. Omura, T., and Sato, R. (1964) The carbon monoxide-binding pigment of liver microsomes. I. Evidence for its hemoprotein nature. *J. Biol. Chem.* **239**, 2370–2378
30. Seo, Y. H., and Carroll, K. S. (2011) Quantification of protein sulfenic acid modifications using isotope-coded dimedone and iododimedone. *Angew. Chem. Int. Ed. Engl.* **50**, 1342–1345
31. Schilling, B., Rardin, M. J., MacLean, B. X., Zawadzka, A. M., Frewen, B. E., Cusack, M. P., Sorensen, D. J., Bereman, M. S., Jing, E., Wu, C. C., Verdin, E., Kahn, C. R., MacCoss, M. J., and Gibson, B. W. (2012) Platform-independent and label-free quantitation of proteomic data using MS1 extracted ion chromatograms in Skyline: application to protein acetylation and phosphorylation. *Mol. Cell Proteomics* **11**, 202–214
32. Kurono, S., Kurono, T., Komori, N., Niwayama, S., and Matsumoto, H. (2006) Quantitative proteome analysis using D-labeled *N*-ethylmaleimide and <sup>13</sup>C-labeled iodoacetanilide by matrix-assisted laser desorption/ionization time-of-flight mass spectrometry. *Bioorg. Med. Chem.* **14**, 8197–8209
33. Zabet-Moghaddam, M., Kawamura, T., Yatagai, E., and Niwayama, S. (2008) Electrospray ionization mass spectroscopic analysis of peptides modified with *N*-ethylmaleimide or iodoacetanilide. *Bioorg. Med. Chem. Lett.* **18**, 4891–4895
34. Lin, T. Y., and Kim, P. S. (1989) Urea dependence of thiol-disulfide equilibria in thioredoxin: confirmation of the linkage relationship and a sensitive assay for structure. *Biochemistry* **28**, 5282–5287
35. Gupta, V., and Carroll, K. S. (2014) Sulfenic acid chemistry, detection and cellular lifetime. *Biochim. Biophys. Acta* **1840**, 847–875
36. Parsonage, D., and Claiborne, A. (1995) Analysis of the kinetic and redox properties of NADH peroxidase C42S and C42A mutants lacking the cysteine-sulfenic acid redox center. *Biochemistry* **34**, 435–441
37. Muller, D. N., Schmidt, C., Barbosa-Sicard, E., Wellner, M., Gross, V., Hercule, H., Markovic, M., Honeck, H., Luft, F. C., and Schunck, W. H. (2007) Mouse Cyp4a isoforms: enzymatic properties, gender- and strain-specific expression, and role in renal 20-hydroxyeicosatetraenoic acid formation. *Biochem. J.* **403**, 109–118
38. Omura, T., and Sato, R. (1964) The carbon monoxide-binding pigment of liver microsomes. II. Solubilization, purification, and properties. *J. Biol. Chem.* **239**, 2379–2385
39. Imai, Y., Horie, S., Yamano, T., and Iizuka, T. (1978) Molecular properties. in *Cytochrome P-450* (Sato, R., and Omura, T., eds) pp. 37–135, Academic Press, Inc., New York
40. Murakami, K., and Mason, H. S. (1967) An electron spin resonance study of microsomal Fe<sub>x</sub>. *J. Biol. Chem.* **242**, 1102–1110
41. Franklin, M. R. (1972) The incomplete conversion of hepatic cytochrome P-450 to P-420 by mercurials. *Mol. Pharmacol.* **8**, 711–721
42. Malinouski, M., Zhou, Y., Belousov, V. V., Hatfield, D. L., and Gladyshev, V. N. (2011) Hydrogen peroxide probes directed to different cellular compartments. *PLoS One* **6**, e14564
43. Kuthan, H., and Ullrich, V. (1982) Oxidase and oxygenase function of the microsomal cytochrome P450 monooxygenase system. *Eur. J. Biochem.* **126**, 583–588
44. Guengerich, F. P., Martin, M. V., Beaune, P. H., Kremers, P., Wolff, T., and Waxman, D. J. (1986) Characterization of rat and human liver microsomal cytochrome P-450 forms involved in nifedipine oxidation, a prototype for genetic polymorphism in oxidative drug metabolism. *J. Biol. Chem.* **261**, 5051–5060
45. Guengerich, F. P., Hosea, N. A., and Martin, M. V. (1998) Purification of cytochromes P450: products of bacterial recombinant expression systems. *Methods Mol. Biol.* **107**, 77–83
46. Choudhury, K., Sundaramoorthy, M., Hickman, A., Yonetani, T., Woehl, E., Dunn, M. F., and Poulos, T. L. (1994) Role of the proximal ligand in peroxidase catalysis: crystallographic, kinetic, and spectral studies of cytochrome *c* peroxidase proximal ligand mutants. *J. Biol. Chem.* **269**, 20239–20249
47. Marnett, L. J., Weller, P., and Battista, J. R. (1986) Comparison of the peroxidase activity of hemoproteins and cytochrome P-450. in *Cyto-*

## P450 4A11 sulfenic acid and inhibition

- chrome P-450 (Ortiz de Montellano, P. R., ed) pp. 29–76, Plenum Press, New York
48. Everse, J., Everse, K. E., and Grisham, M. B. (1991) *Peroxidases in Chemistry and Biology*, Vols. I and II, CRC Press, Boca Raton, FL
  49. Martinez, S., Wu, R., Sanishvili, R., Liu, D., and Holz, R. (2014) The active site sulfenic acid ligand in nitrile hydratases can function as a nucleophile. *J. Am. Chem. Soc.* **136**, 1186–1189
  50. Forman, H. J., Davies, M. J., Krämer, A. C., Miotto, G., Zaccarin, M., Zhang, H., and Ursini, F. (2017) Protein cysteine oxidation in redox signaling: caveats on sulfenic acid detection and quantification. *Arch. Biochem. Biophys.* **617**, 26–37
  51. Guengerich, F. P., Krauser, J. A., and Johnson, W. W. (2004) Rate-limiting steps in oxidations catalyzed by rabbit cytochrome P450 1A2. *Biochemistry* **43**, 10775–10788
  52. Imig, J. D., Zou, A. P., Stec, D. E., Harder, D. R., Falck, J. R., and Roman, R. J. (1996) Formation and actions of 20-hydroxyeicosatetraenoic acid in rat renal arterioles. *Am. J. Physiol.* **270**, R217–R227
  53. Sun, C. W., Falck, J. R., Harder, D. R., and Roman, R. J. (1999) Role of tyrosine kinase and PKC in the vasoconstrictor response to 20-HETE in renal arterioles. *Hypertension* **33**, 414–418
  54. Hazelton, G. A., and Lang, C. A. (1980) Glutathione contents of tissues in the aging mouse. *Biochem. J.* **188**, 25–30
  55. Hoch, U., and Ortiz De Montellano, P. R. (2001) Covalently linked heme in cytochrome P450 4A fatty acid hydroxylases. *J. Biol. Chem.* **276**, 11339–11346
  56. LeBrun, L. A., Hoch, U., and Ortiz de Montellano, P. R. (2002) Autocatalytic mechanism and consequences of covalent heme attachment in the cytochrome P450 4A family. *J. Biol. Chem.* **277**, 12755–12761
  57. Hsu, M. H., Baer, B. R., Rettie, A. E., and Johnson, E. F. (2017) The crystal structure of cytochrome P450 4B1 (CYP4B1) monooxygenase complexed with octane discloses several structural adaptations for  $\omega$ -hydroxylation. *J. Biol. Chem.* **292**, 5610–5621
  58. Fan, F., Ge, Y., Lv, W., Elliott, M. R., Muroya, Y., Hirata, T., Booz, G. W., and Roman, R. J. (2016) Molecular mechanisms and cell signaling of 20-hydroxyeicosatetraenoic acid in vascular pathophysiology. *Front. Biosci.* **21**, 1427–1463
  59. Sreedhar, B., Reddy, P. S., and Madhavi, M. (2007) Rapid and catalyst-free  $\alpha$ -halogenation of ketones using *N*-halosuccinamides in DMSO. *Synth. Commun.* **37**, 4149–4156
  60. Goswami, P., Ali, S., Khan, M. M., and Khan, A. T. (2007) Selective and effective oxone-catalysed  $\alpha$ -iodination of ketones and 1,3-dicarbonyl compounds in the solid state. *Arkivoc* **2007**, 82–89
  61. Shriner, R. L., and Todd, H. R. (1943) 5,5-Dimethyl-1,3-cyclohexanedione. *Org. Syntheses* **2**, 200–202
  62. Niwayama, S., Kurono, S., and Matsumoto, H. (2003) Synthesis of  $^{13}\text{C}$ -labeled iodoacetanilide and application to quantitative peptide analysis by isotope differential mass spectrometry. *Bioorg. Med. Chem. Lett.* **13**, 2913–2916
  63. Kawashima, H., Naganuma, T., Kusunose, E., Kono, T., Yasumoto, R., Sugimura, K., and Kishimoto, T. (2000) Human fatty acid  $\omega$ -hydroxylase, CYP4A11: determination of complete genomic sequence and characterization of purified recombinant protein. *Arch. Biochem. Biophys.* **378**, 333–339
  64. Hanna, I. H., Teiber, J. F., Kokones, K. L., and Hollenberg, P. F. (1998) Role of the alanine at position 363 of cytochrome P450 2B2 in influencing the NADPH- and hydroperoxide-supported activities. *Arch. Biochem. Biophys.* **350**, 324–332
  65. Guengerich, F. P. (2005) Reduction of cytochrome  $b_5$  by NADPH-cytochrome P450 reductase. *Arch. Biochem. Biophys.* **440**, 204–211
  66. Guengerich, F. P. (2014) Analysis and characterization of enzymes and nucleic acids relevant to toxicology, in *Hayes' Principles and Methods of Toxicology*, 6th Ed. (Hayes, A. W., and Kruger, C. L., eds) pp. 1905–1964, CRC Press-Taylor & Francis, Boca Raton, FL
  67. Vaclavikova, R., Soucek, P., Svobodova, L., Anzenbacher, P., Simek, P., Guengerich, F. P., and Gut, I. (2004) Different *in vitro* metabolism of paclitaxel and docetaxel in humans, rats, pigs, and minipigs. *Drug Metab. Dispos.* **32**, 666–674
  68. Yamazaki, H., Gillam, E. M., Dong, M. S., Johnson, W. W., Guengerich, F. P., and Shimada, T. (1997) Reconstitution of recombinant cytochrome P450 2C10(2C9) and comparison with cytochrome P450 3A4 and other forms: effects of cytochrome P450-P450 and cytochrome P450- $b_5$  interactions. *Arch. Biochem. Biophys.* **342**, 329–337
  69. Hanna, I. H., Kim, M. S., and Guengerich, F. P. (2001) Heterologous expression of cytochrome P450 2D6 mutants, electron transfer, and catalysis of bufuralol hydroxylation: the role of aspartate 301 in structural integrity. *Arch. Biochem. Biophys.* **393**, 255–261
  70. Yamazaki, H., Nakano, M., Imai, Y., Ueng, Y. F., Guengerich, F. P., and Shimada, T. (1996) Roles of cytochrome  $b_5$  in the oxidation of testosterone and nifedipine by recombinant cytochrome P450 3A4 and by human liver microsomes. *Arch. Biochem. Biophys.* **325**, 174–182
  71. Sohl, C. D., and Guengerich, F. P. (2010) Kinetic analysis of the three-step steroid aromatase reaction of human cytochrome P450 19A1. *J. Biol. Chem.* **285**, 17734–17743
  72. Pallan, P. S., Wang, C., Lei, L., Yoshimoto, F. K., Auchus, R. J., Waterman, M. R., Guengerich, F. P., and Egli, M. (2015) Human cytochrome P450 21A2, the major steroid 21-hydroxylase: structure of the enzyme-progesterone substrate complex and rate-limiting C–H bond cleavage. *J. Biol. Chem.* **290**, 13128–13143
  73. Yun, C. H., Kim, K. H., Calcutt, M. W., and Guengerich, F. P. (2005) Kinetic analysis of oxidation of coumarins by human cytochrome P450 2A6. *J. Biol. Chem.* **280**, 12279–12291
  74. Shimada, T., and Guengerich, F. P. (2006) Inhibition of human cytochrome P450 1A1-, 1A2-, and 1B1-mediated activation of procarcinogens to genotoxic metabolites by polycyclic aromatic hydrocarbons. *Chem. Res. Toxicol.* **19**, 288–294
  75. MacLean, B., Tomazela D. M., Shulman, N., Chambers, M., Finney, G. L., Frewen, B., Kern, R., Tabb, D. L., Liebler, D. C., and MacCoss, M. J. (2010) Skyline: an open source document editor for creating and analyzing targeted proteomics experiments. *Bioinformatics* **26**, 966–968
  76. Tabb, D. L., Fernando, C. G., and Chambers, M. C. (2007) MyriMatch: highly accurate tandem mass spectral peptide identification by multivariate hypergeometric analysis. *J. Proteome Res.* **6**, 654–661
  77. Holman, J. D., Ma, Z. Q., and Tabb, D. L. (2012) Identifying proteomic LC-MS/MS data sets with Bumpshooter and IDPicker. *Curr. Protocol. Bioinform.* 10.1002/0471250953.bi1317s37
  78. Patil, P. V., and Ballou, D. P. (2000) The use of protocatechuate dioxygenase for maintaining anaerobic conditions in biochemical experiments. *Anal. Biochem.* **286**, 187–192
  79. Burleigh, B. D., Jr., Foust, G. P., and Williams, C. H., Jr. (1969) A method for titrating oxygen-sensitive organic redox systems with reducing agents in solution. *Anal. Biochem.* **27**, 536–544